Skip to main content
Print Save

Generic Adlarity Availability

Last updated on Nov 7, 2023.

Adlarity is a brand name of donepezil, approved by the FDA in the following formulation(s):

ADLARITY (donepezil hydrochloride - system;transdermal)

  • Manufacturer: CORIUM
    Approval date: March 11, 2022
    Strength(s): 5MG/DAY [RLD], 10MG/DAY [RLD]

Has a generic version of Adlarity been approved?

No. There is currently no therapeutically equivalent version of Adlarity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adlarity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
    Patent 10,016,372
    Issued: July 10, 2018
    Inventor(s): Singh Parminder & Lee Eun Soo & Jain Amit K.
    Assignee(s): Corium International, Inc.

    A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

    Patent expiration dates:

    • July 26, 2037
      ✓ 
      Patent use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
  • Donepezil transdermal delivery system
    Patent 10,300,025
    Issued: May 28, 2019
    Inventor(s): Lee Eun Soo & Jain Amit K. & Singh Parminder
    Assignee(s): Corium, Inc.

    A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

    Patent expiration dates:

    • July 26, 2037
      ✓ 
      Drug product
  • Donepezil transdermal delivery system
    Patent 10,307,379
    Issued: June 4, 2019
    Inventor(s): Lee Eun Soo & Jain Amit K. & Singh Parminder
    Assignee(s): Corium, Inc.

    A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

    Patent expiration dates:

    • July 26, 2037
      ✓ 
      Drug product
  • Systems and methods for long term transdermal administration
    Patent 10,835,499
    Issued: November 17, 2020
    Inventor(s): Lee Eun Soo & Jain Amit K. & Singh Parminder
    Assignee(s): Corium, Inc.

    Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

    Patent expiration dates:

    • May 20, 2038
      ✓ 
      Patent use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
      ✓ 
      Drug product
  • Systems comprising a composite backing and methods for long term transdermal administration
    Patent 10,966,936
    Issued: April 6, 2021
    Inventor(s): Lee Eun Soo & Jain Amit K. & Singh Parminder
    Assignee(s): Corium, Inc.

    Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

    Patent expiration dates:

    • August 11, 2038
      ✓ 
      Patent use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
      ✓ 
      Drug product
  • Methods for treating alzheimer's disease with donepezil transdermal system
    Patent 11,103,463
    Issued: August 31, 2021
    Inventor(s): Lee Eun Soo & Jain Amit K. & Singh Parminder
    Assignee(s): Corium, Inc.

    A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

    Patent expiration dates:

    • July 26, 2037
      ✓ 
      Patent use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
  • Patent 11,648,214
    Issued: November 30, -0001

    Patent expiration dates:

    • September 23, 2037
      ✓ 
      Patent use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
      ✓ 
      Drug product
  • Patent 11,679,086
    Issued: November 30, -0001

    Patent expiration dates:

    • May 26, 2037
      ✓ 
      Patent use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
  • Donepezil transdermal delivery system
    Patent 9,993,466
    Issued: June 12, 2018
    Inventor(s): Lee Eun Soo & Jain Amit K. & Singh Parminder
    Assignee(s): Corium International, Inc.

    A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

    Patent expiration dates:

    • July 26, 2037
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • March 11, 2025 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer